| Literature DB >> 34095170 |
Wenxue Hu1, Guanglan Li1,2, Jieshan Lin3, Wei Dong1, Feng Yu1, Wei Liu1, Yanhua Wu1, Wenke Hao1, Xinling Liang1.
Abstract
Objectives: The role of M2 macrophages in the pathogenesis and progression of primary membranous nephropathy (PMN) remains unknown. In this study, we aimed to investigate the relationship between M2 subsets and clinicopathological features of patients with PMN.Entities:
Keywords: M2 macrophages; M2 subpopulations; complement; immunoglobulin; primary membranous nephropathy
Year: 2021 PMID: 34095170 PMCID: PMC8175664 DOI: 10.3389/fmed.2021.657232
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Patients’ characteristics.
| Number of patients | 55 |
| Male ( | 33 (60) |
| Female ( | 22 (40) |
| Hypertensive patients ( | 31 (56.4) |
| Diabetic patients ( | 8 (14.5) |
| Age (years, mean ± SD) | 54.64 ± 14.41 |
| eGFRCKD−EPI (ml/min/1.73 m2, mean ± SD) | 67.81 ± 27.68 |
| Proteinuria [mg/day, M (1/4, 3/4)] | 5345.20 (3297.60, 10204.90) |
| SCr [μmol/L, M (1/4, 3/4)] | 83.04 (70.47, 109.46) |
| BUN [mmol/L, M (1/4, 3/4)] | 5.88 (4.77, 7.52) |
| Cystatin-C [mg/L, M (1/4, 3/4)] | 1.07 (0.85, 1.38) |
| Albumin [g/L, M (1/4, 3/4)] | 23.70 (18.70, 28.50) |
eGFR, estimating glomerular filter rate; SCr, serum creatinine; BUN, blood urea nitrogen.
The pathological data.
| – | 36 (65.5) |
| + | 16 (29.1) |
| ++ | 3 (5.5) |
| 0 | 53 (96.5) |
| 1 | 0 (0.0) |
| 2 | 2 (3.5) |
| II | 44 (80) |
| III | 11 (20) |
| ++ | 4 (7.3) |
| + + + | 51 (92.7) |
| – | 15 (27.3) |
| + | 39 (70.9) |
| – | 50 (90.9) |
| + | 5 (9.1) |
| – | 6 (10.9) |
| + | 8 (14.5) |
| ++ | 37 (67.3) |
| + + + | 4 (7.3) |
| – | 55 (100) |
| – | 21 (38.2) |
| + | 16 (29.1) |
| ++ | 17 (30.9) |
| + + + | 1 (1.8) |
| – | 34 (61.8) |
| + | 19 (34.5) |
| ++ | 2 (3.6) |
| – | 27 (49.1) |
| + | 21 (38.2) |
| ++ | 6 (10.9) |
| + + + | 1 (1.8) |
| – | 3 (5.5) |
| + | 3 (5.5) |
| ++ | 10 (18.2) |
| + + + | 39 (70.9) |
| – | 9 (16.4) |
| + | 46 (83.6) |
| – | 6 (10.9) |
| + | 49 (89.1) |
–, absent; +, mild; ++, moderate; + + +, severe; IgG, immunoglobulin G; IgM, immunoglobulin M; IgA, immunoglobulin A; C3, complement 3; C1q, complement 1q; IgG1, immunoglobulin G1; IgG2, immunoglobulin G2; IgG3, immunoglobulin G3; IgG4, immunoglobulin G4; PLA2R, M-type phospholipase A2 receptor; C4d, complement 4d.
Figure 1Subpopulations of M2 macrophage in glomeruli of PMN patients. M2a macrophages were positive for CD206 by immunochemistry, M2b macrophages were positive for CD86, and M2c macrophages were positive for CD163. The arrows point to positive cells.
The numbers of M2 macrophage subpopulations.
| M2a | 0.65 (0.15, 1.15) |
| M2b | 0.67 (0.33, 1.50) |
| M2c | 0.80 (0.05, 2.30) |
| Macrophage | 1.83 (1.00, 2.67) |
Figure 2The comparison of M2 macrophage subpopulations count in glomeruli between stage II and stage III of membranous nephropathy. Quantitative analysis of CD68, M2a, M2b, and M2c in membranous nephropathy stage II and stage III, Significant correlation *p < 0.05.
Correlation between M2 macrophage subpopulations and clinical and pathologic data.
| eGFRCKD−EPI (ml/min/1.73 m2) | ||||
| Proteinuria (mg/day) | ||||
| SCr (μmol/L) | ||||
| BUN (mmol/L) | ||||
| Cystatin-C (mg/L) | ||||
| Albumin | r = −0.331 | |||
| Glomerular sclerosis | ||||
| IgG | ||||
| IgM | ||||
| IgA | ||||
| C3 | ||||
| IgG1 | ||||
| IgG2 | ||||
| IgG3 | ||||
| IgG4 | ||||
| PLA2R | ||||
| C4d | ||||
Significant correlation
p < 0.05.
Figure 3The correlation between glomerular sclerosis and clinical features and macrophages in glomeruli. Compare estimating glomerular filter rate (A), serum creatinine (B), Cystre-C (C), Proteinuria (D), and macrophage (E) between patients with glomerular sclerosis and patients without glomerular sclerosis. Significant correlation *p < 0.05, **p < 0.01.